immunotherapy

News

Immunotherapy plus chemo: benefits in lung cancer neoadjuvant treatment

Adding a check point inhibitor to chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC) produced significant improvements of pathological complete response (pCR) in comparison to chemotherapy alone. The CheckMate-816…

Articles

Natural killers: a new tactical unit joins the cancer immunotherapy brigade

There was a time when all that oncologists treating solid tumours needed to know about leukocytes was how to measure the damage that cytotoxic drugs inflicted on their patients’ white blood cell…

Articles

Immunotherapy toxicities demand a joined up approach from oncologists and organ specialists

Adverse effects of cancer therapies have long been at the root of decision making for interventions in all modalities – surgery, radiotherapy and medical – and especially in the latter category of…

News

Immunotherapy cardiotoxicity higher than previously estimated

Cancer patients receiving immunotherapy drugs have a much higher incidence of cardiac events than previous estimates from pharmacovigilance data, reports a nationwide Danish registry. The study, published in the European Heart Journal,…

News

Serious patient-reported outcomes data gap in immunotherapy trials revealed

A review of trials of immunotherapy agents revealed a ‘considerable gap’ in the use of patient reported outcomes (PROs), reports a recent study. The data analysis study found PROs were included in…